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Burkitt’s lymphoma (BL) is the third most common solid 
tumour occurring in children in Africa, being exceeded only 
by brain tumours and Wilms' tumour. This is due to the high 
incidence of endemic BL (estimated at 40 - 100 per million 
per year in children under 15)1 in the ‘lymphoma belt’, 
an area from 10o north to 10o south of the equator, which 
corresponds roughly with the malaria belt. The ability of 
the Epstein-Barr virus (EBV) to transform lymphocytes by 
inducing the translocations typically found in BL appears to 
be augmented by malarial parasitaemia. These translocations 
involve the c-Myc oncogene on chromosome 8 and one of the 
immunoglobulin heavy or light chain loci on chromosomes 2, 
14 and 22.
The endemic form found in these areas is characterised by 
a jaw mass (58%), with or without abdominal disease (58%). 
Bone marrow involvement is rare (7%) but central nervous 
system involvement is more common (19%). The sporadic form 
found throughout the Western world typically presents as an 
abdominal mass (88%). Bone marrow involvement is more 
common than in the endemic form (21%) while jaw masses 
(14%) and central nervous system involvement (11%) are less 
common.2 In South Africa most cases fall into the sporadic 
group. 
This review examines the evolution in treatment for BL at 
Red Cross War Memorial Children’s Hospital (RCCH) between 
1984 and 2004. With the use of protocol 1 (P1) and aggressive 
surgery during the 1980s, excellent results were being achieved 
for patients with extensive localised disease. This was however 
at the cost of considerable surgical morbidity, and the outcomes 
of patients with bone marrow and central nervous system 
involvement remained dismal. A more intensive regimen, 
protocol 2 (P2), was introduced during the late 1980s, first for 
those with disseminated disease, and then for localised disease. 
At the same time a consensus was emerging internationally 
that with more intensive chemotherapy, debulking of large 
abdominal tumours was no longer necessary.3 In addition, 
relook surgery to assess disease response after induction 
chemotherapy could be reserved for patients where residual 
disease was suspected.
We undertook this review of patients treated for BL at 
RCCH in order to establish whether our patients with 
disseminated disease have a superior survival with P2 and 
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Background.  Treatment for Burkitt’s lymphoma at Red Cross 
Children’s Hospital has evolved from the use of aggressive 
surgery and less intensive chemotherapy to a conservative 
surgical approach with more intensive chemotherapy.
Methods. The study was a retrospective folder review of 
patients diagnosed with Burkitt’s lymphoma at RCCH between 
1984 and 2004.
Results. Ninety-two children were treated for Burkitt’s 
lymphoma at RCCH between 1984 and 2004. There were 10 
patients with group A or fully resected disease, 52 with group 
B or extensive localised disease, and 30 with dissemination 
to the bone marrow and/or central nervous system or group 
C disease. Protocol 1 (less intensive chemotherapy based on 
the COMP regimen) was used from 1984, with protocol 2 
(more intensive chemotherapy based on the LMB regimen) 
introduced in 1988 for group C disease, 1991 for group B 
disease and 1996 for group A disease. Overall 5-year survival 
increased from 20% with protocol 1 to 66% with protocol 2 for 
group C disease, and from 76.5% with protocol 1 to 88.2% with 
protocol 2 for group B disease. There were more admissions 
for neutropenic fever in patients on protocol 2 and more 
episodes of mucositis, and these patients required more red cell 
and platelet transfusions. With a more conservative surgical 
approach, biopsy largely replaced attempts to partially resect 
the tumour at primary surgery, and there was a consequent 
decline in surgical complications.
Conclusions. Intensive chemotherapy with protocol 2 has 
resulted in improved survival for group C and group B 
patients, but with more morbidity.  Protocol 1, which is less 
intensive with less morbidity, remains a viable strategy for 
group A and group B disease in resource-poor settings.
S Afr Med J 2006; 96: 950-954.
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whether the outcome for extensive localised disease improved 
despite the increased toxicity associated with more intensive 
chemotherapy. 
Methods
The study was a retrospective folder review of patients 
diagnosed with BL at RCCH between 1984 and 2004. Patients 
were identified from the Oncology Registry of the RCCH 
Haematology-Oncology Service. Data on each patient were 
collected from the hospital notes.  Four HIV-positive patients 
presented with BL between 2003 and 2004. These patients were 
treated with antiretroviral therapy and an alternative protocol, 
and were excluded from this study.
The diagnosis of BL was made on histological examination. 
Upon diagnosis, staging for each patient involved bilateral 
bone marrow biopsy, and examination of the cerebrospinal 
fluid (CSF). Chest X-ray and ultrasound of the abdomen were 
mandatory, and CT scans of the head, chest or abdomen were 
obtained where indicated.
During the early years of the study, tumours were partially 
or completely resected where possible. More recently this was 
gradually superseded by biopsy (via laparotomy or laparoscopy) 
for all but small localised intra-abdominal tumours. Definitive 
surgery was performed in patients presenting with intraluminal 
complications such as intussusception. When the diagnosis 
could be made from the bone marrow, or cerebrospinal, pleural 
or ascitic fluid, surgical biopsy was not performed. 
The patients were divided into groups according to the 
risk stratification devised by the French Paediatric Oncology 
Society4 (Table I).
Two chemotherapy protocols were used, P1 based on the 
COMP arm of United States Children’s Cancer Group protocol 
CCG-551,5 and P2 based on the French Paediatric Oncology 
Society protocol LMB-89 (Fig. 1).6 P2 was introduced for group 
C patients in 1988, for group B patients in 1991, and for group 
A patients in 1996.
All patients were treated with allopurinol, hyperhydration 
and urinary alkalinisation at the commencement of induction 
chemotherapy to prevent tumour lysis syndrome. Granulocyte 
colony stimulating factor at a dose of 5 µg/kg per day for 
14 days was used in an attempt to shorten the period of 
neutropenia following intensive chemotherapy in P2.
Originally, second-look laparotomy was often performed 
as part of the review of advanced abdominal disease after 
induction chemotherapy. Later, it was reserved for cases where 
there was clinical or radiological suspicion of residual disease.
Relapse-free and overall survival were estimated by the 
method of Kaplan and Meier. Survival analysis was performed 
using Statistica 6.1 (Statsoft, Inc. 1984 - 2003).
Results
Ninety-two HIV-negative patients with BL were admitted to 
RCCH between January 1988 and December 2004. There were 
64 males and 28 females, with a male/female ratio of  2.3:1. The 
patients ranged in age from 1.6 to 13.95 years, with a median 
age of 5.53 years. The two treatment cohorts had an almost 
identical demographic profile.
Seventy patients (76%) presented with symptoms related to 
abdominal disease, including pain, distension and vomiting. 
Nine patients presented with a jaw mass, and 6 with a neck 
mass. Four presented with generalised adenopathy and bone 
pain, and 3 with paresis due to paraspinal masses.
At diagnosis 77 (83.6%) were found to have abdominal 
disease. Fifty-nine had bowel involvement, including 10 with 
intussusception. Twenty patients had disease involving the 
liver and 10 had renal involvement. Thirteen patients had 
involvement of the uterus, ovary or bladder and 1 patient had 
involvement of the testes. Twenty-five patients had ascites. 
Nine patients (9.8%) had jaw masses and 12 patients had 
pleural effusions. 
Fifteen patients (16.3%) had central nervous system 
involvement at diagnosis. Three had paraspinal masses, 4 had 
central nervous system masses with cranial nerve palsies, and 
11 had blasts in the cerebrospinal fluid. Twenty-five patients 
(27.2%) had more than 25% blasts in the bone marrow. Ten of 
these patients also had central nervous system involvement. 
In all, 30 patients (32.6%) had group C disease; 15 with 
leukaemia, 5 with central nervous system involvement and 
10 with both. Ten patients (10.9%) had group A disease; 9 had 
fully resected localised abdominal lymphomas and 1 cervical 
adenopathy. The other 52 patients (56.5%), including 6 with 
less than 25% blasts in the bone marrow, had group B disease. 
There were more group C patients in the P2 cohort (40% for 
P2 v. 17% for P1), and less group A patients (5% v. 23%), due to 
the staggered introduction of this protocol. Both cohorts had a 
similar percentage of group B patients (55% v. 60%).
All group A patients had complete resection. Thirteen 
(61.9%) of the abdominal group B and C patients treated with 
P1 but only 8 (15.7%) of those treated with P2 had partial 
resection. Second-look laparotomy was performed for 10 
Table I. Risk stratification for Burkitt’s lymphoma (devised 
by the French Pediatric Oncology Society)
Group A   Complete surgical resection of stage I or 
abdominal stage II
Group B   All patients not eligible for group A or 
group C
Group C    Any tumour with CNS involvement
Any tumour with more than 25% blasts in 
the bone marrow
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(33.3%) patients treated with P1 – in 
all but 1 case as a routine procedure. 
Fourteen (22.5%) of those treated with 
P2 underwent relook laparotomy 
– all had a residual mass on clinical 
examination or imaging. In only 4 of 
these 24 cases was there histological 
evidence of lymphoma, and in all cases 
this was strongly suspected on clinical 
examination and imaging.
All group A patients on both 
protocols survived. The estimated 
5-year overall survival for group B 
patients was 76.5% with P1, and 88.2% 
with P2 (p = 0.35) (Fig. 2). There were 
5 deaths with P1, 4 from recurrent 
lymphoma and 1 in remission as a 
result of varicella encephalitis. Five 
of those treated with P2 died: 2 had 
recurrent lymphoma, 1 developed 
bowel infarction and peritonitis 
following surgery for tumour-related 
intestinal obstruction, and 2 deaths were 
treatment-related – 1 during induction 
with haemorrhagic oesophagitis, and 1 
in remission with cerebral aspergillosis.
The estimated 5-year overall survival 
for group C patients was 20.0% with 
P1, and 66.0% with P2 (p = 0.04) (Fig. 
3). All 4 deaths with P1 were the result 
of BL recurrence. Of those treated with 
P2, 6 died of recurrent disease, and 2 
deaths were treatment-related. Both of 
these occurred during induction – 1 as a 
result of Gram-negative septicaemia and 
1 due to mucormycosis.
Twenty-eight patients (30.4%) 
developed tumour lysis syndrome 
requiring some form of medical 
intervention. Three of these patients 
were treated with P1 and none required 
dialysis, whereas 25 were treated 
with P2 and 12 of them required 
either peritoneal or haemodialysis.  
All patients requiring dialysis had 
high tumour burdens with extensive 
abdominal disease (2), leukaemia (7) or 
large pleural effusions (3). 
Twelve of the 49 abdominal group 
B and C patients who had laparotomy 
with biopsy or partial resection had 
surgical complications. These included 
adhesive small-bowel obstruction (6), 
anastomotic leaks or perforations (6), 
volvulus (1) and jejunal obstruction 
(1). Of the 13 in the P1 cohort who had 
partial resection, 5 patients (38.5%) 
experienced complications – mainly 
anastomotic leaks. Two of the 8 patients 
(25%) in the P2 cohort who underwent 
partial resection suffered adhesive 
small-bowel obstruction.
There were 26 episodes of 
neutropenic fever with P1 (0.9 episodes 
per patient) compared with 192 in the 
group treated with P2 (3.1 episodes per 
patient). There were also more positive 
blood cultures in the P2 cohort (0.94 
per patient) compared with the P1 
cohort (0.27 per patient). Transfusion 
requirements were higher for the P2 
cohort. These patients required 4.1 
red cell transfusions and 4.0 platelet 
transfusions per patient compared 
with 1.4 and 0.6 respectively for those 
treated with P1. Severe mucositis was 
more frequent with P2 (1.9 episodes per 
patient) compared with P1 (0.3 episodes 
per patient).
Among group B patients treated 
with P2, 88% required at least one red 
cell transfusion and 62% at least one 
platelet transfusion. Ninety-one per 
cent of patients suffered an episode of 
febrile neutropenia, and 97% suffered 
severe mucositis. Frequency of episodes 
BURKITT LYMPHOMA PROTOCOL ONE
(based on the COMP arm of United States Children’s Cancer Group protocol CCG-551)
INDUCTION    MAINTENANCE (monthly for 6 
     cycles)
Cyclophosphamide 1 200 mg/m2 IV  Cyclophosphamide 1 000 mg/m2 IV
Prednisone 60 mg/m2 PO daily for 28 days Prednisone 60 mg/m2 PO daily for 5 days
Vincristine 2 mg/m2 IV weekly x 4   Vincristine 1.5 mg/m2 IV x 2
Methotrexate IT   Methotrexate IT
Methotrexate 300 mg/m2 IV   Methotrexate 300 mg/m2 IV
BURKITT LYMPHOMA PROTOCOL TWO
(based on the French Paediatric Oncology Society protocol LMB-89)
GROUP A 1. Cyclophosphamide 250 mg/m2 IV 12-hourly x 6  2 cycles
Vincristine 2 mg/m2 IV x 2
Prednisone 60 mg/m2 PO/day x 5 days
Doxorubicin 30 mg/m2 IV daily x 2
GROUP B 1. Cyclophosphamide 300 mg/m2 IV  1 - 2 cycles
Vincristine 1 mg/m2 IV
Methotrexate + Hydrocortisone IT
Prednisone 60 mg/m2 PO daily for 7 days
2. Vincristine 2 mg/m2 IV  2 cycles
Methotrexate 3 g/m2 IV over 3 hours
Prednisone 60 mg/m2 PO daily for 5 days
Cyclophosphamide 250 mg/m2 IV 12-hourly x 6
Doxorubicin 30 mg/m2 IV daily x 2
Methotrexate + Hydrocortisone IT x 2
3. Methotrexate 3 g/m2 IV over 3 hours  2 cycles
Cytarabine 100 mg/m2 IV daily x 5
Methotrexate/Cytarabine + Hydrocortisone IT x 2
4. Repeat 2 … but …  1 cycle
Cyclophosphamide 500 mg/m2 IV daily x 2
Methotrexate + Hydrocortisone IT x 1
GROUP C 1. As for Group B … but …   1 - 2 cycles
Methotrexate + Hydrocortisone + Cytarabine IT x 3   
2. As for Group B … but …  2 cycles
Methotrexate 8 g/m2 IV over 4 hours
Methotrexate + Hydrocortisone + Cytarabine IT x 3
Cyclophosphamide 500 mg/m2 IV 12 hourly x 6 for 2nd cycle
3. Cytarabine 50 mg/m2 IV x 5  2 cycles
Cytarabine 2000 mg/m2 IV x 4
Etoposide 100 mg/m2 IV x 5 
Methotrexate + Hydrocortisone IT x 1 for CNS disease
Methotrexate 8 g/m2 IV and triple IT therapy between cycles for CNS disease
4. Repeat 2 … but …  1 cycle
Cyclophosphamide 500 mg/m2 IV daily x 2
Methotrexate + Hydrocortisone + Cytarabine IT x 1
Fig. 1. Protocols used for Burkitt's lymphoma at RCCH, 1984 - 2004.
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of neutropenic fever and severe mucositis, as well as red cell 
and platelet requirements, were particularly high for group C 
patients treated with P2.
Discussion
BL was first described by Dennis Burkitt in Uganda in 1958 as 
a ‘sarcoma involving the jaw in African children’.7 He observed 
its dramatic response to chemotherapy, demonstrating a 
number of long-term remissions with one or two doses of 
cyclophosphamide.8 Further evaluation showed that this 
endemic variant was clinically related, and histologically 
identical, to the abdominal form9 that constitutes the sporadic 
variant. Initially treatment consisted of surgical cytoreduction 
where possible and chemotherapy.10
The subsequent evolution of BL treatment has seen the use 
of increasingly intensive chemotherapy and a reduction in the 
role of surgery. Early work demonstrated increased survival 
where complete resection could be achieved,11 and advocated 
an aggressive surgical approach to BL.12 As the efficacy of 
chemotherapy regimens improved, it became obvious that 
aggressive attempts at surgical cytoreduction delayed the 
administration of chemotherapy, and were associated with an 
increase in complications requiring surgical intervention.13,14
Debulking surgery to reduce tumour bulk no longer appears 
to be necessary. Surgery is now only required for diagnostic 
purposes, or in the event of surgical complications of the 
lymphoma such as intestinal obstruction. 
While regimens such as COMP,15 on which P1 was based, 
proved very effective for patients with localised disease, cure 
for those with dissemination to the bone marrow or central 
nervous system remained elusive. Successive studies by groups 
in France16,17 and the USA18 showed that high cure rates could 
be obtained with more intensive chemotherapy. The French 
reported a 5-year overall survival of 100% for group A, 94% for 
group B and 85% for group C.6  
Our patients fitted the profile of the sporadic type of BL. 
Abdominal disease predominated (83.6%) with few jaw masses 
(9.8%), and bone marrow involvement (27.2%) was more 
common than central nervous system involvement (16.3%). 
As in all other series males predominated but the median age 
(5.53 years) is younger than that reported in the French study 
(8 years). This is presumably the result of almost universal 
exposure to EBV at a young age. The high rate of dissemination 
to the bone marrow and/or central nervous system (32.6%) 
illustrates the ongoing problem of late diagnosis of childhood 
malignancy in South Africa. There were only 21.9% group C 
patients in the French study.6
The introduction of P2 improved the estimated 5-year overall 
survival for group C patients from 20.0% for those treated with 
P1 to 66.0% for those treated with P2 (p = 0.04). There is a trend 
for improved survival among group B patients with an increase 
in the estimated 5-year overall survival from 76.5% with P1 to 
88.2% with P2 (p = 0.35). The group B results are comparable to 
the 94% reported by the French, but the group C results are still 
disappointing compared with the 85% reported in the French 
study.6
Side-effects of chemotherapy have increased with the 
introduction of P2. Group B and C patients had more episodes 
of neutropenic fever and severe mucositis, and higher blood 
product requirements. There were 4 treatment-related deaths 
with P2 – 2 in group B and 2 in group C – and there was a high 
rate of tumour lysis requiring dialysis.
Our patients appear to have experienced more side-effects 
than those treated in the French study. Treatment-related 
mortality was higher among both our group B patients (5.9% 
v. 0.8%) and our group C patients (8% v. 4.1%). Our group B 
patients required more red cell transfusions (88% v. 58%) and 
platelet transfusions (62% v. 17%), and suffered more episodes 
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Group C Burkitt Lymphoma 1984 - 2004








































Fig. 3. Estimated overall 5-year survival for group C Burkitt’s lymphoma, 
1984 - 2004.
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Fig. 2. Estimated overall 5-year survival for group B Burkitt’s lymphoma, 
1984 - 2004.
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of febrile neutropenia (91% v. 82%) and severe mucositis (97% 
v. 38%).6
Partial tumour resection among group B and C patients 
declined from 61.9% with P1 to 15.7% with P2. At the same 
time the surgical complication rate following complete or 
partial resection declined from 38.5% with P1 (more than half 
of them anastomotic leaks) to 25% with P2 (both adhesive 
small-bowel obstruction). Second-look laparotomy rates also 
decreased from 33.3% on P1 to 22.5% on P2. Laparoscopy has 
been increasingly used for diagnosis in place of laparotomy, 
with the aim of minimising adhesions and consequent bowel 
obstructions.
In conclusion, the introduction of more intensive 
chemotherapy for the treatment of BL at RCCH has resulted in 
a marked increase in survival for patients with disseminated 
disease. Survival has improved more modestly for extensive 
localised disease, but this has been accompanied by increased 
morbidity, which appears to exceed that reported in the 
French study. A more conservative surgical approach to BL has 
decreased the surgical complication rate.
In our unit patients with extensive localised disease treated 
with P1 attained a 76.5% estimated 5-year overall survival. This 
compares favourably to the 62% failure-free survival reported 
in the original USA study,4 and the 77.4% event-free survival 
reported in Lebanon for locally advanced disease.19 Only one 
death in our P1 cohort was treatment-related, and toxicity was 
mainly limited to neutropenic fever and anaemia requiring red 
cell transfusion.
While regimens similar to P2 (also based on the French 
LMB protocol) are used in other South African centres,20 less 
intensive regimens such as P1 are still used in the developing 
world. These regimens with their low side-effect profile and 
minimal transfusion requirements are ideal for African centres 
with limited resources, and are recommended for children with 
group B BL in these settings.
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